Behind every breakthrough is a team of chemists, biologists, clinicians and innovators asking new questions and designing smarter solutions.
At LightOx, our work in light-activated therapies began with a simple question born from scientific curiosity: what if treatment could be controlled by light? Today, that question is shaping a new approach to managing precancerous oral lesions.
Here’s how.
It often starts silently.
A small white patch on the inside of the cheek. A red patch on the side of the tongue that doesn’t look quite right and doesn’t go away. No pain. No urgency. Easy to overlook.
Yet sometimes, these subtle changes are precancerous lesions that can progress into more serious disease.
Traditionally, patients have faced limited options: invasive surgery with long recovery times, or a “watch and wait” approach that can leave uncertainty lingering for years.
At LightOx, we believe there’s a third way. Our team is developing light-activated therapies that can be applied directly to the affected area and activated with light, enabling clinicians to treat abnormal tissue in a controlled and localised way while helping preserve surrounding healthy structures.
What Are Light-Activated Therapies?
Light-activated therapies use specially designed molecules that remain inactive until exposed to specific wavelengths of light. Once illuminated, these molecules trigger a therapeutic effect, such as selectively killing cancerous cells in the treated area.
This approach is different from traditional chemotherapy or radiotherapy, which can affect healthy tissue and cause widespread side effects. By activating treatment only where light is applied, clinicians can control where and when the therapy works, minimising unnecessary harm while maximising impact.
How LightOx Is Making a Difference
Our lead candidate, LXD191, is a topical gel applied directly to early-stage oral lesions. Once activated with a handheld light device (like dental curing lights), the compound becomes active only in the illuminated area, allowing clinicians to treat the abnormal tissue locally. Preclinical studies have shown that LXD191 can effectively induce cell death in abnormal tissue, while helping minimise damage to surrounding structures.
Beyond oral cancer, our platform is also being explored for antimicrobial therapies helping tackle resistant infections in wounds, demonstrating the versatility of light-activated technologies.
Why Early Intervention Matters
Catching disease early isn’t just about treatment, it’s about protecting the things that make life feel normal. Surgery in the mouth can affect speech, chewing, and even the way someone smiles. Long-term radiotherapy can bring dry mouth, scarring, and lingering complications that impact day-to-day life.
Light-activated therapies take a different approach. By allowing treatment to be applied locally to the affected area, they provide clinicians with a controlled and repeatable way to intervene earlier while minimising disruption to surrounding tissue. That means patients can intervene earlier, with less disruption, and maintain their quality of life while taking control of their health.
Looking Ahead
At LightOx, we’re taking our preclinical successes forward into the clinic. With strong partnerships and support, we have laid the groundwork for first-in-human trials of LXD191 in 2026.
Our mission is simple: bring safe, effective, and accessible therapies to patients who need them most, while advancing science in a way that’s impactful and inclusive for all.
Curiosity has always been at the heart of scientific progress. At LightOx, that same curiosity continues to guide our work as we explore how light-activated therapies could open new possibilities for patients.
Want to follow our journey from lab to clinic?
Stay updated on our progress, new insights, and upcoming milestones.
